Financhill
Back

Exelixis Quote, Financials, Valuation and Earnings

Exelixis Price Quote

$23.70
+0.17 (+0.72%)
(Updated: April 26, 2024 at 6:55 PM ET)

Exelixis Key Stats

Buy
53
Exelixis (EXEL) is a Buy

Day range:
$23.36 - $23.74
52-week range:
$18.08 - $24.34
Dividend yield:
0%
P/E ratio:
36.20
P/S ratio:
4.13
P/B ratio:
3.15%

Volume:
1.4M
Avg. volume:
2.1M
1-year change:
24.83%
Market cap:
$7.1B
Revenue:
$1.8B
EPS:
$0.64

How Much Does Exelixis Make?

  • How Much Are Exelixis's Sales Annually?
    EXEL Revenues are $1.8B
  • How Much Profit Does Exelixis's Make A Year?
    EXEL net income is $207.8M

Is Exelixis Growing As A Company?

  • What Is Exelixis's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.13%
  • What Is Exelixis's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Exelixis Stock Price Performance

  • Did Exelixis Stock Go Up Last Month?
    Exelixis share price went down by -0.72% last month
  • Did EXEL's Share Price Rise Over The Last Year?
    EXEL share price rose by 24.83% over the past 1 year

What Is Exelixis 52-Week High & Low?

  • What Is Exelixis’s 52-Week High Share Price?
    Exelixis has traded as high as $24.34 over the past 52 weeks
  • What Is Exelixis’s 52-Week Low Share Price?
    Exelixis has traded as low as $18.08 over the past 52 weeks

Exelixis Price To Free Cash Flow

  • Is Exelixis Stock Overvalued?
    Exelixis is trading at a price to free cash flow ratio of 44.40
  • Is Exelixis Stock Undervalued?
    Exelixis EV to Free Cash Flow ratio is 36.04
  • What Is Exelixis’s Price Earnings Growth Ratio?
    EXEL PEG ratio is 2.85
  • Is Exelixis Trading At A Premium To Earnings?
    Exelixis EV to EBIT ratio is 35.92

Is It Risky To Buy Exelixis?

  • How Much Debt Does Exelixis Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Exelixis Have?
    Cash and short term investments quarterly total is $995.3M
  • What Is Exelixis’s Book Value Per Share?
    Book value per share is 7.48

Is Exelixis Cash Flow Positive?

  • What Is EXEL Cash Flow From Operations?
    Cash flow from operations (TTM) is $333.3M
  • What Is Exelixis’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$546.1M
  • What Is Exelixis’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$27M

Exelixis Return On Invested Capital

  • Is Management Doing A Good Job?
    EXEL return on invested capital is 8.53%
  • What Is Exelixis Return On Assets?
    ROA measures how assets are converting to revenues and is 6.8%
  • What Is EXEL Return On Equity?
    ROE is a measure of profitability and is 8.53%

Exelixis Earnings Date & Stock Price

  • What Is Exelixis's Stock Price Today?
    A single share of EXEL can be purchased today for 23.53
  • What Is Exelixis’s Stock Symbol?
    Exelixis trades on the nasdaq under the ticker symbol: EXEL
  • When Is Exelixis’s Next Earnings Date?
    The next quarterly earnings date for Exelixis is scheduled on April 30, 2024
  • When Is EXEL's next ex-dividend date?
    Exelixis's next ex-dividend date is April 27, 2024
  • How To Buy Exelixis Stock?
    You can buy Exelixis shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Exelixis Competitors

  • Who Are Exelixis's Competitors?
    Below is a list of companies who compete with Exelixis or are related in some way:
    • Bristol-Myers Squibb Co (BMY)
    • Johnson & Johnson (JNJ)
    • Legend Biotech Corp (LEGN)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Bio-Techne Corp (TECH)

Exelixis Dividend Yield

Data Unavailable

Exelixis Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 6.8%
Revenue: 13.15% 0.36%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 26.63
Upside from Last Price: 13.19%

Major Shareholders

  • How many EXEL shares are owned by institutional investors?
    377.8M EXEL shares are owned by institutional investors
  • How many EXEL shares are owned by insiders?
    8.9M EXEL shares are owned by insiders